share_log

Daiwa Upgrades Bristol-Myers Squibb(BMY.US) to Buy Rating, Raises Target Price to $65

Futu News ·  Nov 14 18:31  · Ratings

Daiwa analyst Narumi Nakagiri upgrades $Bristol-Myers Squibb (BMY.US)$ to a buy rating, and adjusts the target price from $54 to $65.

According to TipRanks data, the analyst has a success rate of 75.0% and a total average return of 12.1% over the past year.

AnalystRecentRatingAutoNews_205930_20241113_6e99d822fa3aa3de53dac9e7ba691aff2c01c76b_1731580232254190_nn_en

Furthermore, according to the comprehensive report, the opinions of $Bristol-Myers Squibb (BMY.US)$'s main analysts recently are as follows:

  • The unexpected update on the Phase 2 results of emraclidine by AbbVie has led to revisions in revenue projections. With emraclidine being excluded from projections and an increase in Cobenfy estimates for Bristol Myers, there is a 7% rise in total expected revenue for 2033. This revision, however, does not alter the general trajectory of revenue or earnings per share growth for the companies involved.

  • Analysts noted that pivotal Phase 2 data for a competing schizophrenia treatment did not meet statistical significance in demonstrating change from baseline in a key symptom scale. This underperformance was unexpected, especially considering the treatment was a major factor in a significant acquisition and was projected to bring in substantial sales while competing with an established product. While the long-term outlook for the established product may improve as a result, there are still immediate concerns regarding patent exclusivity.

  • The failure of a competing drug, Emraclidine, to demonstrate a statistically significant benefit at the primary endpoint in its Phase 2 studies, places Bristol's Cobenfy in a favorable position. Given the underwhelming results that may send rivals back to the drawing board, it's pivotal for Bristol to capitalize on the opportunity and successfully launch Cobenfy.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment